We are Sarepta Therapeutics: a biopharmaceutical company focused on developing innovative RNA-targeted therapeutics. Our goal is to harness the power of cutting-edge technology to improve the lives of people affected by rare, infectious and other diseases.
Today’s Research Reports on Trending Tickers: Novavax and Sarepta Therapeutics Tue, 14 Nov 2017 13:10:00 +0000 NEW YORK, NY / ACCESSWIRE / November 14, 2017 / After posting its first weekly loss in two months on Friday, the Dow Jones and S&P 500 Index opened the week in the green on Monday. The Dow Jones Industrial ...
[$$] Sarepta: Too Much Good News to Ignore Fri, 10 Nov 2017 13:25:00 +0000 Sarepta Therapeutics (SRPT) has moved to solidify its position as the leading company in the treatment of Duchenne muscular dystrophy (DMD) with the recent announcement of three new clinical trials. Sarepta CEO Doug Ingram called the Anthem move “a fantastic result for children with DMD” in a Barron’s interview Thursday. The selloff probably reflects hedging activity by convertible arbitragers who purchased the big Sarepta convertible.
Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment Thu, 09 Nov 2017 20:07:17 +0000 The U.S. Food and Drug Administration approved Sarepta for Duchenne, a degenerative disease that mostly affects young boys, last year despite questions from experts and its own reviewers about the efficacy of the drug. An Anthem spokeswoman said its medical policy committee had reviewed information presented at recent scientific meetings, feedback from clinicians and information from Sarepta before making the change. Sarepta Chief Executive Doug Ingram said the move was encouraging for children with the disease because it could loosen up strict policies at health insurers who have tight controls on covering the treatment.
Sarepta: Payers Gonna Pay? Thu, 09 Nov 2017 14:35:00 +0000 Sarepta Therapeutics (SRPT) got some good news today when health insurer Anthem (ANTM) decided to cover the treatment of Sarepta’s drug for Duchenne muscular dystrophy, Exondys 51, in ambulatory patients, ...
Sarepta Therapeutics Prices $475 Million of Convertible Senior Notes Due 2024 Wed, 08 Nov 2017 23:45:00 +0000 CAMBRIDGE, Mass., Nov. 08, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.